Rockwell Medical, Inc. (DE) financials
$8.68+0.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.3M | $101.5M | $83.6M | $72.8M | $61.9M | $62.2M | $61.3M | $63.4M | $57.3M | $53.3M |
| Gross profit | $11.7M | $17.5M | $8.7M | $4.1M | -$2.4M | $2.7M | $2.8M | -$1.6M | $3.7M | $6.8M |
| Gross margin | 16.9% | 17.2% | 10.4% | 5.6% | −3.9% | 4.4% | 4.6% | −2.5% | 6.5% | 12.7% |
| Operating income | -$4.7M | $608.0K | -$6.7M | -$16.8M | -$30.3M | -$28.4M | -$34.5M | -$32.4M | -$25.9M | -$20.2M |
| Net income | -$5.3M | -$480.0K | -$8.4M | -$18.7M | -$32.7M | -$30.9M | -$34.1M | -$32.1M | -$25.9M | -$19.8M |
| Net margin | −7.7% | −0.5% | −10.1% | −25.7% | −52.8% | −49.7% | −55.7% | −50.7% | −45.2% | −37.2% |
| Diluted EPS | $-1.50 | $-0.30 | $-3.70 | $-13.10 | $-38.30 | $-45.10 | $-61.60 | $-67.10 | $-56.10 | $-42.90 |
| EBITDA | -$2.5M | $2.8M | -$5.2M | -$16.2M | -$29.7M | -$27.6M | -$33.3M | -$30.8M | -$25.4M | -$19.4M |
| Operating cash flow | -$659.0K | $4.2M | -$9.4M | -$16.9M | -$33.5M | -$29.6M | -$27.3M | -$20.7M | -$21.1M | -$12.5M |
| Free cash flow | -$1.2M | $3.2M | -$9.7M | -$17.2M | -$34.1M | -$30.7M | -$27.8M | -$21.4M | -$22.8M | -$12.8M |
| Diluted shares | 3.6M | 3.1M | 2.3M | 1.4M | 0.9M | 0.7M | 0.6M | 0.5M | 0.5M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.7M | $15.7M | $9.0M | $10.1M | $13.3M | $48.7M |
| Short-term investments | $14.3M | $5.9M | $2.0M | $11.4M | $9.2M | $10.0M |
| Total debt | $9.9M | $10.3M | $10.6M | $12.3M | $21.0M | $20.9M |
| Total assets | $57.1M | $59.2M | $52.2M | $46.6M | $48.6M | $77.7M |
| Total liabilities | $20.2M | $26.6M | $30.9M | $32.5M | $46.0M | $43.6M |
| Shareholders' equity | $37.0M | $32.6M | $21.3M | $14.1M | $2.5M | $34.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology